Ondansetron

Generic Name: Ondansetron

Brand Names: Zofran, Zuplenz

Drug Type: Small Molecule

Chemical Formula: C_₁₈H_₁₉N_₃O

CAS Number: 99614-02-5

Unique Ingredient Identifier: 4AF302ESOS

Background: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
...

Indication: In the adult patient population:

i) orally administered ondansetron tablets and orally disintegrating tablets (ODT) are indicated for:

- the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including high dose (ie. greater than or equal to 50 mg/m2) cisplatin therapy, and radiotherapy, and
...

Associated Conditions: Chemotherapy-Induced Nausea and Vomiting, Cholestatic pruritus, Post Operative Nausea and Vomiting (PONV), Radiation-Induced Nausea and Vomiting, Uremic Pruritus, Severe Hyperemesis gravidarum

Associated Therapies: -

Clinical Trials

Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

Phase 2

Completed

Conditions: Alcohol Dependence

Interventions: Drug: Placebo
Drug: Ondansetron
Drug: Olanzapine

First Posted Date: 2008-05-15

Last Posted Date: 2009-01-30

Lead Sponsor: University of Virginia

Target Recruit Count: 40

Registration Number: NCT00678457

Locations: 🇺🇸
UVA CARE, Charlottesville, Virginia, United States
🇺🇸
UVA CARE Richmond, Richmond, Virginia, United States

Effect of Acupuncture on Postoperative Nausea and Vomiting

Phase 4

Completed

Conditions: Cholelithiasis

Interventions: Other: Acupuncture
Drug: Ondansetron
Drug: Physiological saline solution
Other: Sham acupuncture
Other: Acupuncture at P6 point

First Posted Date: 2008-05-08

Last Posted Date: 2008-05-08

Lead Sponsor: Catholic University of the Sacred Heart

Target Recruit Count: 140

Registration Number: NCT00674713

Locations: 🇮🇹
Catholic University of Sacred Heart, Rome, Italy

Bioavailability Study of Ondansetron 24 mg Orally Disintegrating Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ondansetron
Drug: Zofran

First Posted Date: 2008-04-16

Last Posted Date: 2008-04-16

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 24

Registration Number: NCT00659074

Locations: 🇨🇦
Algorithme Pharma, Laval, Quebec, Canada

Bioavailability Study of Ondansetron 16 mg Orally Disintegrating Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ondansetron
Drug: Zofran ODT

First Posted Date: 2008-04-16

Last Posted Date: 2008-04-16

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 24

Registration Number: NCT00659685

Locations: 🇨🇦
Algorithme Pharma, Laval, Quebec, Canada

Comparison of Ondansetron, Metoclopramide and Promethazine for the Treatment of Nausea and Vomiting in the Adult ED

Not Applicable

Terminated

Conditions: Nausea

Interventions: Drug: Ondansetron
Drug: Metoclopramide
Drug: Promethazine
Drug: Normal Saline

First Posted Date: 2008-04-10

Last Posted Date: 2013-10-30

Lead Sponsor: Vanderbilt University

Target Recruit Count: 171

Registration Number: NCT00655642

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fed Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Zofran
Drug: Ondansetron

First Posted Date: 2008-04-07

Last Posted Date: 2008-04-11

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 18

Registration Number: NCT00653458

Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ondansetron
Drug: Zofran

First Posted Date: 2008-04-07

Last Posted Date: 2008-04-11

Lead Sponsor: Par Pharmaceutical, Inc.

Target Recruit Count: 32

Registration Number: NCT00654277

Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients

Not Applicable

Completed

Conditions: Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Aprepitant
Drug: Vincristine
Drug: Doxorubicin
Drug: Prednisone
Drug: Rituximab
Drug: Ondansetron

First Posted Date: 2008-04-03

Last Posted Date: 2013-07-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 23

Registration Number: NCT00651755

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Phase 3

Completed

Conditions: Chemotherapy Induced Nausea and Vomiting

Interventions: Drug: dronabinol/ondansetron
Drug: placebo
Drug: dronabinol
Drug: ondansetron

First Posted Date: 2008-03-25

Last Posted Date: 2008-04-03

Lead Sponsor: Solvay Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00642512

Locations: 🇺🇸
Site 943, Rancho Mirage, California, United States
🇺🇸
Site 922, Marietta, Georgia, United States
🇺🇸
Site 905, Southfield, Michigan, United States

and more 40 locations

Treating Benign Paroxysmal Positional Vertigo (BPPV) in ED Patients

Not Applicable

Completed

Conditions: Benign Paroxysmal Positional Vertigo

Interventions: Other: Epley Maneuver
Drug: Meclizine
Drug: Lorazepam
Drug: Diphenhydramine
Drug: Ondansetron

First Posted Date: 2008-03-24

Last Posted Date: 2018-04-03

Lead Sponsor: Lehigh Valley Hospital

Target Recruit Count: 26

Registration Number: NCT00641797

Locations: 🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy